Toll-like receptor 7-mediated type I interferon signaling prevents cholestasis- and hepatotoxin-induced liver fibrosis

Hepatology

Volumn 60, Issue 1, 2014, Pages 237-249

  Roh, Yoon Seok ^a,b   Park, Surim ^a   Kim, Jong Won ^a   Lim, Chae Woong ^a   Seki, Ekihiro ^b   Kim, Bumseok ^a  

^a Chonbuk National University   (South Korea)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA BETA INTERFERON RECEPTOR; ALPHA BETA INTERFERON RECEPTOR 1; ALPHA SMOOTH MUSCLE ACTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TOLL LIKE RECEPTOR 7; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL POPULATION; CHOLESTASIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DENDRITIC CELL; IN VIVO STUDY; KUPFFER CELL; LIVER CELL; LIVER FIBROSIS; LIVER PROTECTION; MACROPHAGE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STELLATE CELL;

ANIMALS; CARBON TETRACHLORIDE; CHOLESTASIS; CHRONIC DISEASE; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; DRUG-INDUCED LIVER INJURY; FEMALE; INTERFERON TYPE I; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; KUPFFER CELLS; LIVER CIRRHOSIS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTOR, INTERFERON ALPHA-BETA; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 7;

EID: 84903174810     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26981     Document Type: Article

References (43)

1. Friedman SL. Liver fibrosis - from bench to bedside. J Hepatol 2003;38(Suppl 1):S38-S53.
2. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-218.
3. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004;4:499-511.
4. Eberle F, Sirin M, Binder M, Dalpke AH. Bacterial RNA is recognized by different sets of immunoreceptors. Eur J Immunol 2009;39:2537-2547.
5. Mancuso G, Gambuzza M, Midiri A, Biondo C, Papasergi S, Akira S, et al. Bacterial recognition by TLR7 in the lysosomes of conventional dendritic cells. Nat Immunol 2009;10:587-594.
6. Guiducci C, Tripodo C, Gong M, Sangaletti S, Colombo MP, Coffman RL, et al. Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9. J Exp Med 2010;207:2931-2942.
7. Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S, et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005;202:1131-1139.
8. Schwabe RF, Seki E, Brenner DA. Toll-like receptor signaling in the liver. Gastroenterology 2006;130:1886-1900.
9. Frances R, Benlloch S, Zapater P, Gonzalez JM, Lozano B, Munoz C, et al. A sequential study of serum bacterial DNA in patients with advanced cirrhosis and ascites. Hepatology 2004;39:484-491.
10. Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007;13:1324-1332.
11. Watanabe A, Hashmi A, Gomes DA, Town T, Badou A, Flavell RA, et al. Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology 2007;46:1509-1518.
12. Kawai T, Akira S. TLR signaling. Semin Immunol 2007;19:24-32.
13. Inagaki Y, Nemoto T, Kushida M, Sheng Y, Higashi K, Ikeda K, et al. Interferon alfa down-regulates collagen gene transcription and suppresses experimental hepatic fibrosis in mice. Hepatology 2003;38:890-899.
14. Fort J, Pilette C, Veal N, Oberti F, Gallois Y, Douay O, et al. Effects of long-term administration of interferon alpha in two models of liver fibrosis in rats. J Hepatol 1998;29:263-270.
15. Petrasek J, Dolganiuc A, Csak T, Kurt-Jones EA, Szabo G. Type I interferons protect from Toll-like receptor 9-associated liver injury and regulate IL-1 receptor antagonist in mice. Gastroenterology 2011;140:697-708 e694.
16. Tanabe J, Izawa A, Takemi N, Miyauchi Y, Torii Y, Tsuchiyama H, et al. Interferon-beta reduces the mouse liver fibrosis induced by repeated administration of concanavalin A via the direct and indirect effects. Immunology 2007;122:562-570.
17. Alric L, Duffaut M, Selves J, Sandre K, Mularczyck M, Izopet J, et al. Maintenance therapy with gradual reduction of the interferon dose over one year improves histological response in patients with chronic hepatitis C with biochemical response: results of a randomized trial. J Hepatol 2001;35:272-278.
18. Omata M, Shiratori Y. Long-term effects of interferon therapy on histology and development of hepatocellular carcinoma in hepatitis C. J Gastroenterol Hepatol 2000;15(Suppl):E134-E140.
19. Hiramatsu N, Hayashi N, Kasahara A, Hagiwara H, Takehara T, Haruna Y, et al. Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha. J Hepatol 1995;22:135-142.
20. Fort J, Pilette C, Veal N, Oberti F, Gallois Y, Douay O, et al. Effects of long-term administration of interferon alpha in two models of liver fibrosis in rats. J Hepatol 1998;29:263-270.
21. Duncan MR, Berman B. Persistence of a reduced-collagen-producing phenotype in cultured scleroderma fibroblasts after short-term exposure to interferons. J Clin Invest 1987;79:1318-1324.
22. Goldring MB, Sandell LJ, Stephenson ML, Krane SM. Immune interferon suppresses levels of procollagen mRNA and type II collagen synthesis in cultured human articular and costal chondrocytes. J Biol Chem 1986;261:9049-9055.
23. Chou MH, Huang YH, Lin TM, Du YY, Tsai PC, Hsieh CS, et al. Selective activation of Toll-like receptor 7 in activated hepatic stellate cells may modulate their profibrogenic phenotype. Biochem J 2012;447:25-34.
24. Georgiev P, Navarini AA, Eloranta JJ, Lang KS, Kullak-Ublick GA, Nocito A, et al. Cholestasis protects the liver from ischaemic injury and post-ischaemic inflammation in the mouse. Gut 2007;56:121-128.
25. Shi Z, Wakil AE, Rockey DC. Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc Natl Acad Sci U S A 1997;94:10663-10668.
26. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004;303:1529-1531.
27. Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, Gale NW, et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A 2004;101:5598-5603.
28. Stockinger S, Kastner R, Kernbauer E, Pilz A, Westermayer S, Reutterer B, et al. Characterization of the interferon-producing cell in mice infected with Listeria monocytogenes. PLoS Pathog 2009;5:e1000355.
29. Tun-Kyi A, Finn G, Greenwood A, Nowak M, Lee TH, Asara JM, et al. Essential role for the prolyl isomerase Pin1 in Toll-like receptor signaling and type I interferon-mediated immunity. Nat Immunol 2011;12:733-741.
30. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002;3:196-200.
31. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009;27:519-550.
32. Chou MH, Huang YH, Lin TM, Du YY, Tsai PC, Hsieh CS, et al. Selective activation of Toll-like receptor 7 in activated hepatic stellate cells may modulate their profibrogenic phenotype. Biochem J 2012;447:25-34.
33. Mancini R, Benedetti A, Jezequel AM. An interleukin-1 receptor antagonist decreases fibrosis induced by dimethylnitrosamine in rat liver. Virchows Arch 1994;424:25-31.
34. Isoda K, Sawada S, Ayaori M, Matsuki T, Horai R, Kagata Y, et al. Deficiency of interleukin-1 receptor antagonist deteriorates fatty liver and cholesterol metabolism in hypercholesterolemic mice. J Biol Chem 2005;280:7002-7009.
35. Guarda G, Braun M, Staehli F, Tardivel A, Mattmann C, Forster I, et al. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 2011;34:213-223.
36. Jungo F, Dayer JM, Modoux C, Hyka N, Burger D. IFN-beta inhibits the ability of T lymphocytes to induce TNF-alpha and IL-1beta production in monocytes upon direct cell-cell contact. Cytokine 2001;14:272-282.
37. Nagai T, Devergne O, van Seventer GA, van Seventer JM. Interferon-beta mediates opposing effects on interferon-gamma-dependent Interleukin-12 p70 secretion by human monocyte-derived dendritic cells. Scand J Immunol 2007;65:107-117.
38. McRae BL, Nagai T, Semnani RT, van Seventer JM, van Seventer GA. Interferon-alpha and -beta inhibit the in vitro differentiation of immunocompetent human dendritic cells from CD14(+) precursors. Blood 2000;96:210-217.
39. Guo B, Chang EY, Cheng G. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J Clin Invest 2008;118:1680-1690.
40. Uematsu S, Sato S, Yamamoto M, Hirotani T, Kato H, Takeshita F, et al. Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon-{alpha} induction. J Exp Med 2005;201:915-923.
41. Takaoka A, Yanai H, Kondo S, Duncan G, Negishi H, Mizutani T, et al. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 2005;434:243-249.
42. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005;434:772-777.
43. Sasai M, Linehan MM, Iwasaki A. Bifurcation of Toll-like receptor 9 signaling by adaptor protein 3. Science 2010;329:1530-1534.